All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): TransCon hGH
Therapeutic Area: Endocrinology Product Name: TransCon hGH
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Sequoia China
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing January 09, 2021
Details:
Proceeds of the Series B financing will be used to accelerate the clinical development of the potential best-in-class portfolio drug candidates and to build a strong foundation for commercialization.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dorzagliatin
Therapeutic Area: Endocrinology Product Name: HMS5552
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Bayer HealthCare
Deal Size: $635.8 million Upfront Cash: $43.3 milllion
Deal Type: Partnership August 17, 2020
Details:
Hua Medicine shall be responsible for clinical development, registration, product supply and distribution of dorzagliatin, whilst Bayer as the promotion service provider shall be responsible for marketing, promotion and medical education activities in China.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Dorzagliatin,Metformin
Therapeutic Area: Endocrinology Product Name: HMS5552
Highest Development Status: Phase III Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2020
Details:
All subjects are treated with metformin (Glucophage) at 1500mg/day as basic therapy throughout the entire 52-week treatment period. Study met the primary efficacy and safety endpoints in the double-blinded placebo-controlled and randomized 24-week trial.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
